A carregar...
553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
BACKGROUND: Background:: Immune modulation in patients with clinical features suggestive of a cytokine release syndrome (CRS) has become a pharmacologic target for potential treatment of COVID-19 and prevention of ARDS. Tocilizumab is an IL-6 receptor blocker FDA-approved for chimeric antigen recept...
Na minha lista:
| Publicado no: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7777929/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.747 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|